Labcorp Holdings Inc. (NYSE:LH) Receives Consensus Rating of “Moderate Buy” from Analysts

Labcorp Holdings Inc. (NYSE:LH) has received a consensus recommendation of “Moderate Buy” from the eleven brokerages that are currently covering the firm, Marketbeat reports. Three research analysts have rated the stock with a hold rating and eight have issued a buy rating on the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $308.00.

Several research analysts recently commented on the stock. JPMorgan Chase & Co. raised their price target on shares of Labcorp from $319.00 to $330.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 18th. Piper Sandler raised their target price on shares of Labcorp from $270.00 to $300.00 and gave the company a “neutral” rating in a research report on Tuesday, February 24th. Robert W. Baird set a $334.00 target price on shares of Labcorp in a research report on Friday, May 1st. Morgan Stanley reissued an “overweight” rating on shares of Labcorp in a research report on Tuesday, February 17th. Finally, Weiss Ratings reissued a “buy (b-)” rating on shares of Labcorp in a research report on Friday, May 8th.

Insider Buying and Selling at Labcorp

In other news, CEO Adam H. Schechter sold 5,903 shares of the firm’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $254.50, for a total value of $1,502,313.50. Following the sale, the chief executive officer directly owned 107,234 shares in the company, valued at approximately $27,291,053. This trade represents a 5.22% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.84% of the company’s stock.

Institutional Trading of Labcorp

A number of institutional investors have recently modified their holdings of LH. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in Labcorp in the 4th quarter worth approximately $26,000. Hilton Head Capital Partners LLC acquired a new position in shares of Labcorp in the 4th quarter valued at $27,000. JPL Wealth Management LLC purchased a new stake in Labcorp in the 3rd quarter worth $28,000. Eagle Bay Advisors LLC purchased a new stake in Labcorp in the 4th quarter worth $29,000. Finally, DV Equities LLC purchased a new stake in Labcorp in the 4th quarter worth $29,000. 95.94% of the stock is currently owned by institutional investors.

Labcorp Trading Up 0.8%

LH stock opened at $260.93 on Friday. The company has a market capitalization of $21.40 billion, a PE ratio of 23.11, a P/E/G ratio of 1.81 and a beta of 0.90. Labcorp has a 12 month low of $241.81 and a 12 month high of $293.72. The firm’s 50-day moving average is $262.76 and its 200 day moving average is $265.62. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.73 and a quick ratio of 1.54.

Labcorp (NYSE:LH) last posted its quarterly earnings results on Thursday, April 30th. The medical research company reported $4.25 EPS for the quarter, topping the consensus estimate of $4.09 by $0.16. The company had revenue of $3.54 billion for the quarter, compared to the consensus estimate of $3.51 billion. Labcorp had a net margin of 6.66% and a return on equity of 16.29%. The firm’s revenue was up 5.8% compared to the same quarter last year. During the same quarter last year, the firm posted $3.84 EPS. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. On average, research analysts anticipate that Labcorp will post 18 EPS for the current year.

Labcorp Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, June 11th. Stockholders of record on Friday, May 29th will be issued a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date is Friday, May 29th. Labcorp’s dividend payout ratio (DPR) is currently 25.51%.

Labcorp Company Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.